Financials
Financial year 2025
KC PHARMA from Mol, company number BE0479334705, closed financial year 2025 with a result of € 115,605 after tax. For that financial year KC PHARMA recorded a gross margin of € 158,741 and equity of € 736,030. Compared with financial year 2024, the result moved from € 20,026 to € 115,605. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
€ 736,030
▲ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 115,605
▲ € 95,579 vs 2024
Profit after tax over the fiscal year.
€ 11,932
▼ 46% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 3,360 paid out
3 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 1,076
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 129
▼ 36% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 53,592
▲ 146% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 20,613 | € 31,359 | € 30,046 | € 158,741 | ▲ € 128,694 |
| Profit after taxes | € 13,898 | € 19,742 | € 20,026 | € 115,605 | ▲ € 95,579 |
| Equity | € 584,018 | € 603,759 | € 623,785 | € 736,030 | ▲ 18% |
| Total debts | € 140,275 | € 129,089 | € 109,099 | € 137,266 | ▲ 26% |
| Cash | € 969 | € 29,076 | € 21,980 | € 11,932 | ▼ 46% |
| Retained profit | € 547,518 | € 567,259 | € 587,285 | € 699,530 | ▲ 19% |
| Dividend | € 0 | € 0 | € 0 | € 3,360 | |
| Bank debt | € 1,187 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 724,293 | € 732,848 | € 732,885 | € 873,296 | ▲ 19% |
Key figures of KC PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KC PHARMA?
What happened at KC PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 115,605 (▲ € 95,579 vs 2024). Source: NBB ↗
- KATHLEEN CROUX became a director. NBB
- New establishment in Mol. KBO
- Start of the company according to the CBE. KBO
In short
From € 13,898 profit in 2022 to € 115,605 profit in 2025.
Paid € 71,837 in corporate taxes since 2022.
Best year ever: 2025, with € 115,605 profit.
Paid out € 3,360 in dividends to the owners in total.
Management
Behind KC PHARMA is KATHLEEN CROUX. KATHLEEN CROUX is also behind Stebofisc and TOMKAT.
Establishments
Establishment units
Physical locations of this company
Leeuwerikheide 86
2400 Mol
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0479.334.705
- VAT number
- BE 0479.334.705
- Registered office
- Leeuwerikheide 86, 2400 Mol
- Names & denominations
- KC PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 January 2003
- Peppol
- Active · Active since 16 Jun 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van holdings
Managementactiviteiten van holdings
Holdings